Form 4: Halozyme Therapeutics Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, exercised stock options and sold shares according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 18, 2024, Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, exercised options to purchase 10,000 shares of common stock at a price of $8.11 per share.
• Simultaneously, LaBarre sold 10,000 shares of common stock at a weighted average price of $49.426 per share, with prices ranging from $49.00 to $49.74.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 9, 2023.
• Following these transactions, LaBarre directly owns 168,176 shares of Halozyme Therapeutics common stock and holds options to purchase 11,715 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports routine stock transactions under a pre-arranged plan. There's no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, suggesting they were planned well in advance and not based on immediate insider information.

Industry Context

Executive stock transactions are common and closely monitored, especially in the biotechnology sector. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include stock options as a significant component.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings and avoid insider trading accusations.
• Comparing LaBarre's stock ownership and trading activity with those of executives at similar-sized biotech companies (e.g., Argenx, BioMarin) could provide further context.

Stakeholder Impact

• The stock sale could have a minor, temporary impact on the stock price, but the pre-planned nature of the transactions mitigates concerns.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates